

Mitoxantrone disrupts cardiac metabolism along with proteolysis and regeneration in aged mice


Sofia Reis Brandão^{1,2,3}, Ana Reis-Mendes^{1,2}, Margarida Duarte-Araújo^{4,5}, Maria João Neuparth^{6,7,8}, Félix Carvalho^{1,2}, Rita Ferreira³, Vera Marisa Costa^{1,2}

¹ Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, Porto, Portugal; ² UCIBIO-Applied Molecular Biosciences Unit, REQUIMTE, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal; ³ LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro, Portugal; ⁴ LAQV-REQUIMTE, Faculty of Pharmacy, University of Porto, Porto, Portugal; ⁵ Department of Immuno-Physiology and Pharmacology, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal; ⁶ Research Centre in Physical Activity, Health and Leisure (CIAFEL), Faculty of Sports, University of Porto, Porto, Portugal; ⁷ Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal; ⁸ TOXRUN - Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, Gandra, Portugal.

INTRODUCTION

Mitoxantrone (MTX) is a chemotherapeutic agent used to treat solid tumors and hematological malignancies, as well as multiple sclerosis. Nevertheless, MTX has been associated with serious adverse side effects, such as cardiotoxicity. Considering that aging is a known risk factor for the development of cardiovascular diseases and cancer, our study aimed to assess the molecular effects of MTX on cardiac muscle of aged mice.

METHODOLOGY



Animal experiments were performed with the approval of the national competent authorities - General Directorate of Food and Veterinary Medicine (DGAV, reference nº 0421/000/000/2016) and of the ORBEA of ICBAS-UP (project nº 140/2015). Mice welfare was monitored daily. The experimental groups were statistical compared using two-sided t-test ($p < 0.05$) of GraphPad Prism (version 6.0.1). Results are presented as significantly increased (\uparrow), decreased (\downarrow) or no significantly different (\leftrightarrow) related to the CONTROL group: * $p < 0.05$; ** $p < 0.01$.

RESULTS & DISCUSSION

MTX decreased whole-body weight

Morphometric parameters measured on the day of sacrifice. Results (n = 5-8) represent weight or length.

Whole-body weight (g)	\downarrow *
Heart weight (g)	\leftrightarrow
Tibial length (cm)	\leftrightarrow
Heart weight-to-whole body weight (mg/g)	\leftrightarrow
Heart weight-to-tibial length (g/cm)	\leftrightarrow

MTX increased serum glucose concentration

Biochemical parameters measured on **serum** using an AutoAnalyzer (Prestige 24i, Cormay PZ, Diamond Diagnostics, Holliston, MA, USA). Values (n = 5-8) represent concentration or activity.

Total protein (g/L)	\leftrightarrow	Cholesterol (mg/dL)	\leftrightarrow
Albumin (g/L)	\leftrightarrow	ALAT (U/L)	\leftrightarrow
Glucose (mg/dL)	\uparrow **	CK-MB (U/L)	\leftrightarrow

ALAT: alanine aminotransferase, CK-MB: creatine kinase-MB

MTX decreased cardiac glycolysis, autophagy, proteolysis and regeneration

Proteins measured on **cardiac muscle homogenates** using **Western blotting**. Representative image of the Western blot obtained is presented. Results (n = 6-7) represent optical density.

GLUT4	\downarrow *	Beclin1	\leftrightarrow
PFKM	\downarrow **	ATG5	\downarrow *
ETFDH	\leftrightarrow	LC3B	\leftrightarrow
ATPB	\leftrightarrow	Atrogin	\downarrow *
PGC-1 α	\leftrightarrow	SCFR	\leftrightarrow
Tfam	\leftrightarrow	CITED4	\leftrightarrow
Mitofusin1	\leftrightarrow	CEBP β	\downarrow **

GLUT4: glucose transporter GLUT4, **PFKM**: phosphofructokinase, **ETFDH**: electron transfer flavoprotein ubiquinone-oxidoreductase, **ATPB**: ATP synthase subunit β , **PGC-1 α** : peroxisome proliferator-activated receptor γ coactivator 1 α , **Tfam**: mitochondrial transcription factor A, **ATG5**: autophagy protein 5, **LC3B**: microtubule-associated protein light chain 3, **SCFR**: mast/stem cell growth factor receptor Kit, **CITED4**: Cbp/p300-interacting transactivator 4, **CEBP β** : CCAAT/enhancer-binding protein β

- Old mice administered with MTX showed decreased whole-body weight, suggestive of molecular changes.
- MTX-treated mice are less dependent on glycolysis as cardiac energetic pathway, retrieved by the decreased content of GLUT4 and PFKM on cardiac muscle, despite the increased circulating glucose concentration.
- Moreover, MTX influenced cardiac autophagy, proteolysis, and regeneration, indicated by the decreased content of ATG5, Atrogin, and CEBP β , respectively.
- Future studies should focus on these unexplored pathways as they may explain the cardiotoxicity induced by MTX.

This work was supported by national funds from FCT - Fundação para a Ciência e a Tecnologia, I.P., in the scope of the projects UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO, the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB, the project UIDB/50006/2020 of the LAQV-REQUIMTE Aveiro, the project UIDB/00617/2020 of the CIAFEL, the project LA/P/0064/2020 of the ITR - Laboratory for Integrative and Translational Research in Population Health. SRB, ARM, and VMC acknowledge FCT and European Social Fund (FSE) for their grants (SFRH/BD/138202/2018, SFRH/BD/129359/2017, and SFRH/BPD/110001/2015). VMC grant was given under Norma Transitória DL57/2016/CP1334/CT0006.

sofiarbrandao@ua.pt Copyrights © 2022 Sofia Reis Brandão et al.

ECMC
2022

The 8th International Electronic
Conference on Medicinal Chemistry
01-30 NOVEMBER 2022 | ONLINE